The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), was awarded a $591,372 Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research (CFDA 93.393) program. The goal of this multi-site randomized controlled trial is to evaluate the efficacy of a novel digital application called DREAMLAND for improving quality of life, anxiety, depression, and other patient-reported outcomes in patients with acute myeloid leukemia (AML) undergoing intensive chemotherapy. The project will be conducted at MGH, Duke Cancer Center, and Fred Hutchinson Cancer Research Center, leveraging their expertise in palliative care, supportive care, and digital health interventions for hematologic malignancies. This project aims to obtain FDA approval for DREAMLAND as a digital therapeutic to address the significant psychological and quality of life needs of AML patients. Additionally, MGH has awarded two sub-grants under this project to Duke University and Fred Hutchinson Cancer Research Center to support related research on inpatient palliative care integrated with standard transplant care for patients with hematologic malignancies.
Generated 1/28/25, 9:52 AM